Cardiotoxicity of Non-Cardiovascular Drugs
暂无分享,去创建一个
[1] P. Russo. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma , 2009 .
[2] R. Slavin,et al. Marrow transplanation in man following cyclophosphamide. , 1971, Transplantation proceedings.
[3] G. Brittinger,et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] I. Bernstein,et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] W. Zidek,et al. Erythropoietin increases cytosolic free calcium concentration in vascular smooth muscle cells. , 1993, Cardiovascular research.
[6] P. Rougier,et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] A. Ross,et al. Acute arrhythmogenicity of doxorubicin administration , 1987, Cancer.
[8] M. Ghielmini,et al. A Phase I-II Study to Determine the Maximum Tolerated Infusion Rate of Rituximab with Special Emphasis on Monitoring the Effect of Rituximab on Cardiac Function , 2008, Clinical Cancer Research.
[9] C. V. Strihou,et al. Hypertension after renal transplantation. , 1976, British medical journal.
[10] Brian Walters,et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate , 2006, Nature Medicine.
[11] A. Chan,et al. A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] G. Scagliotti,et al. Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] M. Christian,et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] M. Conrad. Cytarabine and Cardiac Failure , 1992, American journal of hematology.
[15] Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. , 2001 .
[16] D. Porter,et al. Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiation , 2005, Leukemia & lymphoma.
[17] V. Valero,et al. Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] P. Philip,et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] P. C. Viswanathan,et al. New Mechanism Contributing to Drug-Induced Arrhythmia: Rescue of a Misprocessed LQT3 Mutant , 2005, Circulation.
[20] A. Dalgleish,et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] D. Dizon,et al. Dyspnea during Thalidomide Treatment for Advanced Ovarian Cancer , 2005, The Annals of pharmacotherapy.
[22] E. Winer,et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] D. Häussinger,et al. Cardiotoxicity of the Antiprolif erative Compound Fluorouracil , 1999, Drugs.
[24] W. Hait,et al. Tubulin-targeting agents. , 2003, Cancer chemotherapy and biological response modifiers.
[25] M. Blute. Sunitinib in patients with metastatic renal cell carcinoma , 2006 .
[26] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[27] A. Ferrant,et al. Pericarditis induced by high-dose cytosine arabinoside chemotherapy , 1997, Annals of Hematology.
[28] B. Jensen,et al. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] H. White,et al. A case of cardiogenic shock caused by capecitabine treatment , 2008, Nature Clinical Practice Cardiovascular Medicine.
[30] Michael Hawkins,et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Y. Goldsmith,et al. Capecitabine-induced coronary vasospasm. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] K. Shyu. Serotonin 5-HT2B receptor in cardiac fibroblast contributes to cardiac hypertrophy: a new therapeutic target for heart failure? , 2008, Circulation research.
[33] K. Kolaja,et al. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes , 2011, Nature Reviews Drug Discovery.
[34] F. Appelbaum,et al. Radionuclide ejection fractions in the evaluation of patients being considered for bone marrow transplantation: risk for cardiac toxicity. , 1990, Bone marrow transplantation.
[35] J. Baselga,et al. Targeting the microtubules in breast cancer beyond taxanes: the epothilones. , 2007, The oncologist.
[36] A. Castaigne,et al. MYOCARDIAL INFARCTION FOLLOWING VINBLASTINE TREATMENT , 1980, The Lancet.
[37] K. Nugent,et al. Acute Cardiac Toxicity Associated with High‐Dose Intravenous Methotrexate Therapy: Case Report and Review of the Literature , 2005, Pharmacotherapy.
[38] D. Neuberg,et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] M. Talpaz,et al. Vindesine-associated angina and ECG changes. , 1982, Cancer treatment reports.
[40] P. Venugopal,et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. , 2001, Blood.
[41] D P Dearnaley,et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] P. Dombernowsky,et al. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] M. Zaletel,et al. Thrombosis of Internal Carotid Artery after Cisplatin-Based Chemotherapy , 2006, European Neurology.
[44] D. Kuhn,et al. Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade , 2008, Clinical Cancer Research.
[45] G. Hortobagyi,et al. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[46] T. Cerny,et al. Acute Pericarditis and Pleural Effusion Complicating Cytarabine Chemotherapy , 2003, Oncology Research and Treatment.
[47] K. Ness,et al. High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation , 2009, Bone Marrow Transplantation.
[48] C. Becerra,et al. Adverse effects of bevacizumab and their management in solid tumors. , 2006, Supportive cancer therapy.
[49] H. Caron,et al. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. , 2010, The Cochrane database of systematic reviews.
[50] G. Salles,et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] S. Horning,et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] R. Karaoǧuz,et al. Severe vascular toxicity associated with cisplatin‐based chemotherapy , 1993, Cancer.
[53] A. Zander,et al. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation , 2008, Haematologica.
[54] Y. Kanda,et al. Predictors for severe cardiac complications after hematopoietic stem cell transplantation , 2004, Bone Marrow Transplantation.
[55] W. Hahn,et al. Vaccination of Cancer Patients Against Telomerase Induces Functional Antitumor CD8+ T Lymphocytes , 2004, Clinical Cancer Research.
[56] D. V. Von Hoff,et al. Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.
[57] Liu,et al. Acute Doxorubicin Cardiotoxicity Is Associated With p53-Induced Inhibition of the Mammalian Target of Rapamycin Pathway , 2009, Circulation.
[58] R. Herbst,et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] A. Frustaci,et al. Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience. , 2008, Leukemia research.
[60] J. Thigpen. Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study , 2009 .
[61] C. Begg,et al. High-dose ifosfamide with mesna uroprotection: a phase I study. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] R. Pazdur,et al. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. , 2003, The oncologist.
[63] Narine Sarvazyan,et al. Anthracycline cardiotoxicity: from bench to bedside. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] M. Goldberg,et al. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. , 1986, Blood.
[65] Richard J Stephens,et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] B. Cheson,et al. Lenalidomide for the treatment of B-cell malignancies. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] Yeon-Hee Park,et al. BNP as a marker of the heart failure in the treatment of imatinib mesylate. , 2006, Cancer letters.
[68] A. Alencar,et al. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. , 2004, Blood.
[69] S. Rosenberg,et al. Cardiopulmonary toxicity of treatment with high dose interleukin‐2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma , 1994, Cancer.
[70] J. Friedberg,et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[71] E. Winer,et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] D. Wallwiener,et al. Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial. , 2004, European journal of cancer.
[73] G. Silverman,et al. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. , 2003, Arthritis and rheumatism.
[74] G. Peters,et al. A Parallel Dose-Escalation Study of Weekly and Twice-Weekly Bortezomib in Combination with Gemcitabine and Cisplatin in the First-Line Treatment of Patients with Advanced Solid Tumors , 2007, Clinical Cancer Research.
[75] L. Kritharides,et al. Subacute cardiac toxicity following autologous haematopoietic stem cell transplantation in patients with normal cardiac function , 2007, Heart.
[76] R. Maki,et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[77] A Messori,et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. , 2001, The New England journal of medicine.
[78] Robert B. Diasio,et al. Clinical Pharmacology of 5-Fluorouracil , 1989, Clinical pharmacokinetics.
[79] M. Clausen,et al. Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] L. Gianni,et al. Cardiac arrhythmias after cisplatin infusion: three case reports and a review of the literature. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[81] S. Topal,et al. Gemcitabine-Induced Acute Coronary Syndrome: A Case Report , 2008, Medical Principles and Practice.
[82] R. Abonour,et al. Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma. , 2006, Clinical lymphoma & myeloma.
[83] Susumu Minamisawa,et al. ErbB2 is essential in the prevention of dilated cardiomyopathy , 2002, Nature Medicine.
[84] J. Shuster,et al. Results of a Randomized Phase III Trial in Children and Adolescents with Advanced Stage Diffuse Large Cell Non-Hodgkin's Lymphoma: A Pediatric Oncology Group Study , 2002, Leukemia & lymphoma.
[85] M. Suntharalingam,et al. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. , 2008, International journal of radiation oncology, biology, physics.
[86] Jon Sharp,et al. Late congestive heart failure after hematopoietic cell transplantation. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[87] X. H. Chen,et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[88] U. Pelzer. Second-line chemotherapy in advanced pancreatic cancer. , 2008, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[89] T. Robak,et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[90] S. Singhal,et al. Thalidomide in cancer: potential uses and limitations. , 2001, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.
[91] M. Pestrin,et al. Taxanes in the elderly: can we gain as much and be less toxic? , 2009, Critical reviews in oncology/hematology.
[92] M. Wong. The current role of immunotherapy for renal cell carcinoma in the era of targeted therapeutics , 2008, Current oncology reports.
[93] V. Zadnik,et al. Cardiac Toxicity of High-Dose Cyclophosphamide in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation , 2007, International journal of hematology.
[94] Atrial Fibrillation Induced by Gemcitabine Treatment in a 65-Year-Old Man , 2007, Oncology Research and Treatment.
[95] A. Santoro,et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[96] J. Forbes,et al. BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC) , 2007 .
[97] A. Smit,et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[98] J Shaughnessy,et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. , 2001, Blood.
[99] C. Sessa,et al. Ongoing phase I and II studies of novel anthracyclines , 2007, Cardiovascular Toxicology.
[100] R. Pazdur,et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[101] Haiyi Jiang,et al. Overview of gefitinib in non-small cell lung cancer: an Asian perspective. , 2008, Japanese journal of clinical oncology.
[102] M. Gordon,et al. Phase III Trial of Consolidation Therapy With Yttrium-90-Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma , 2009 .
[103] J. Kirkwood,et al. Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma , 2008, Cancer.
[104] Orciuolo Enrico,et al. Unexpected cardiotoxicity in haematological bortezomib treated patients. , 2007, British journal of haematology.
[105] L. Ford,et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. , 2005, Journal of the National Cancer Institute.
[106] Y. Ramot,et al. Drug-Induced Thrombosis—Experimental, Clinical, and Mechanistic Considerations , 2007, Toxicologic pathology.
[107] M. Gordon. Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma , 2006 .
[108] W. Dahut,et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[109] S. Lipsitz,et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[110] M. Mazumdar,et al. Arsenic trioxide and low‐dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia , 2008, Cancer.
[111] H. Kantarjian,et al. Congestive heart failure is a rare event in patients receiving imatinib therapy. , 2006, Blood.
[112] M. Vassilomanolakis,et al. Ifosfamide cardiotoxicity in humans , 2004, Cancer Chemotherapy and Pharmacology.
[113] W. Scheithauer,et al. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[114] S. Palmer,et al. Cardiovascular risk in long‐term survivors of testicular cancer , 2008, Cancer.
[115] J. Irani. [Sunitinib versus interferon-alpha in metastatic renal-cell carcinoma]. , 2007, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.
[116] A. Baumelou,et al. Acute cardiac and renal failure after 5-FU and cisplatin treatment. , 1991, Nephron.
[117] N. Geller,et al. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[118] F. Ognibene,et al. High-Dose Ifosfamide Is Associated with Severe, Reversible Cardiac Dysfunction , 1993, Annals of Internal Medicine.
[119] J. Armitage,et al. Acute coronary syndromes complicating the first infusion of rituximab. , 2008, Clinical lymphoma & myeloma.
[120] S. Allerheiligen,et al. Preclinical, pharmacologic, and phase I studies of gemcitabine. , 1997, Seminars in oncology.
[121] M. Lader,et al. Cardiovascular effects of antidepressants , 1990, Psychological medicine. Monograph supplement.
[122] T. Younis. Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma , 2003, British journal of haematology.
[123] Y. Ko,et al. Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[124] T. Vial,et al. Immune-mediated side-effects of cytokines in humans. , 1995, Toxicology.
[125] K. Schultz,et al. Cardiac manifestations of graft-versus-host disease. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[126] H. Choy,et al. Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue , 2008, Clinical Cancer Research.
[127] Y. Martinet,et al. Cisplatin-induced atrial fibrillation. , 1991, Journal of Clinical Oncology.
[128] T. Tabei,et al. Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes. , 2005, Japanese journal of clinical oncology.
[129] José Manuel Cervera Grau,et al. Complete atrioventricular block induced by rituximab in monotherapy in an aged patient with non-Hodgkin’s diffuse large B-cell lymphoma , 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.
[130] N. Hanna. Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial , 2008 .
[131] M. Mori,et al. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[132] C. Hudis,et al. Cardiac dysfunction in the trastuzumab clinical trials experience. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[133] Patrick F. Smith,et al. Gemcitabine and Acute Myocardial Infarction , 2006, Angiology.
[134] A. Hacıhanefioğlu,et al. Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib , 2008, International journal of hematology.
[135] F. Ognibene,et al. Cardiorespiratory effects of immunotherapy with interleukin-2. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[136] S. De Flora,et al. Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention , 2010, Journal of the National Cancer Institute.
[137] L. Gianni,et al. Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.
[138] F. Kabbinavar,et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[139] Shenhong Wu,et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. , 2008, JAMA.
[140] S. Cosimo,et al. A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER 2 expression : changing the natural history of HER 2-positive disease , 2006 .
[141] O. Hermine,et al. Severe cardiac toxicity after monoclonal antibody therapy , 2002, European journal of haematology.
[142] K. Brunner,et al. Neurologic and cardiac toxicity following iv application of methotrexate. , 1982, Cancer treatment reports.
[143] J. Forbes,et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[144] K. Woodside,et al. Alemtuzumab (Campath 1H) as successful salvage therapy for recurrent steroid-resistant heart transplant rejection. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[145] T. Xu,et al. Cyclophosphamide‐evoked heart failure involves pronounced co‐suppression of cytoplasmic thioredoxin reductase activity and non‐protein free thiol level , 2009, European journal of heart failure.
[146] A. Camm,et al. Drug induced QT prolongation and torsades de pointes , 2003, Heart.
[147] Maurizio Recanatini,et al. Safety of Non-Antiarrhythmic Drugs that Prolong the QT Interval or Induce Torsade de Pointes , 2002, Drug safety.
[148] J. Forbes,et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[149] A. Ribeiro,et al. An evaluation of the cardiotoxicity of imatinib mesylate. , 2008, Leukemia research.
[150] P. Steinherz,et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. , 1991, JAMA.
[151] R. Riccardi,et al. Anthracycline-related cardiotoxicity: risk factors and therapeutic options in childhood cancers , 2008 .
[152] R. Ohno,et al. Prolongation of the QT Interval and Ventricular Tachycardia in Patients Treated with Arsenic Trioxide for Acute Promyelocytic Leukemia , 2000, Annals of Internal Medicine.
[153] E. Topol,et al. Risk of cardiovascular events associated with selective COX-2 inhibitors. , 2001, JAMA.
[154] A. López-Guillermo,et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.
[155] T. Kuzel,et al. Results of a Phase II trial of oral bexarotene (Targretin) combined with interferon alfa‐2b (Intron‐A) for patients with cutaneous T‐cell lymphoma , 2007, Cancer.
[156] J. Jassem,et al. Evaluation of trastuzumab (Herceptin®), docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer , 2007 .
[157] S. Hirschfeld,et al. FDA drug approval summaries: oxaliplatin. , 2004, The oncologist.
[158] Greg Yothers,et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[159] C. Tournigand,et al. [Cardiotoxicity of 5-fluorouracil]. , 2004, Bulletin du cancer.
[160] Z. Sasson,et al. 5-Fluorouracil related toxic myocarditis: case reports and pathological confirmation. , 1994, The Canadian journal of cardiology.
[161] P. Rochaix,et al. Preclinical Toxicity, Toxicokinetics, and Antitumoral Efficacy Studies of DTS-201, a Tumor-Selective Peptidic Prodrug of Doxorubicin , 2008, Clinical Cancer Research.
[162] U. Hofmann,et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[163] G. Batist,et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[164] J. Nabholtz. Long-term safety of aromatase inhibitors in the treatment of breast cancer , 2008, Therapeutics and clinical risk management.
[165] R. Diasio,et al. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. , 1988, The Journal of clinical investigation.
[166] C. Kuropkat,et al. Severe cardiotoxicity during 5-fluorouracil chemotherapy: a case and literature report. , 1999, American journal of clinical oncology.
[167] N. Hanna,et al. Vinorelbine Plus Cisplatin vs Observation in Resected Non–Small-Cell Lung Cancer , 2006 .
[168] D. Weisdorf,et al. Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977–1997 , 2001, Bone Marrow Transplantation.
[169] M. Dyer,et al. No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome. , 2005, Blood.
[170] J. Cuzick,et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. , 2006, The Lancet. Oncology.
[171] S. Bhatia,et al. Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation , 2008, British journal of haematology.
[172] J. Baynes,et al. The anti-cancer drug, doxorubicin, causes oxidant stress-induced endothelial dysfunction. , 2006, Biochimica et biophysica acta.
[173] Francisco Cervantes,et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.
[174] Han‐Chung Wu,et al. Anti-Angiogenic Therapeutic Drugs for Treatment of Human Cancer , 2008 .
[175] D. G. Wenzel. Drug-induced cardiomyopathies. , 1967, Journal of pharmaceutical sciences.
[176] J. Gottdiener,et al. Cardiotoxicity associated with high-dose cyclophosphamide therapy. , 1981, Archives of internal medicine.
[177] J. Dalzell,et al. The spectrum of 5-fluorouracil cardiotoxicity , 2009, Anti-cancer drugs.
[178] S. Soignet,et al. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[179] A. Burnett,et al. Chemotherapy‐induced cardiotoxicity: current practice and prospects of prophylaxis , 2002, European journal of heart failure.
[180] K. Hirata,et al. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer , 2008, Journal of Translational Medicine.
[181] Y. Lee,et al. Complete Atrioventricular Block after Arsenic Trioxide Treatment in an Acute Promyelocytic Leukemic Patient , 1999, Pacing and clinical electrophysiology : PACE.
[182] K. Hess,et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[183] M. Somerfield,et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[184] P. Lønning,et al. Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial , 2007, The Lancet.
[185] J. Reckelhoff. Sex steroids, cardiovascular disease, and hypertension: unanswered questions and some speculations. , 2005, Hypertension.
[186] Ma Dong,et al. Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .
[187] R. Kurzrock,et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders , 2003, Cancer.
[188] I. Filipović,et al. Capecitabine cardiotoxicity--case reports and literature review. , 2008, Hepato-gastroenterology.
[189] D. Vaughn,et al. Cardiovascular late effects and the ongoing care of adult cancer survivors. , 2008, Disease management : DM.
[190] P. Campochiaro,et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. , 2006, Ophthalmology.
[191] F. Shepherd,et al. Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer , 2007 .
[192] M. Sonnenblick,et al. Cardiotoxicity of interferon. A review of 44 cases. , 1991, Chest.
[193] J. Grygiel,et al. Hypercholesterolemia after chemotherapy for testis cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[194] J. Bourhis,et al. Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[195] S. Colan,et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. , 1991, The New England journal of medicine.
[196] R. Diasio,et al. Predicting fluorouracil toxicity: can we finally do it? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[197] Stanley B. Cohen,et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. , 2006, Arthritis and rheumatism.
[198] N. Robert,et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[199] O. Press. Evidence mounts for the efficacy of radioimmunotherapy for B-cell lymphomas. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[200] J. Berenson,et al. A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma , 2007, Clinical Cancer Research.
[201] M. Chen,et al. Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics , 2008, Circulation.
[202] J. Feliu,et al. Cardiac toxicity: old and new issues in anti-cancer drugs , 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.
[203] C. Hudis,et al. Tolerance of bevacizumab in an older patient population: The Memorial Sloan-Kettering Cancer Center (MSKCC) experience , 2008 .
[204] A. Eisen,et al. Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review. , 2008, Cancer treatment reviews.
[205] David Zurakowski,et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib , 2007, The Lancet.
[206] D. Lake,et al. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[207] S. Swain,et al. The Epothilones: Translating from the Laboratory to the Clinic , 2008, Clinical Cancer Research.
[208] M. Lapeyre-Mestre,et al. Vinorelbine‐related cardiac events: a meta‐analysis of randomized clinical trials , 2004, Fundamental & clinical pharmacology.
[209] P. Sevelda,et al. Thrombosis with paclitaxel , 1994, The Lancet.
[210] S. Martino,et al. Reversible arrhythmias observed in patients treated with recombinant alpha2 interferon , 2004, Journal of Cancer Research and Clinical Oncology.
[211] N. Vogelzang,et al. Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin , 1985, Cancer.
[212] C. Hawkey,et al. Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors , 2003, Gut.
[213] J. Byrd,et al. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia , 2007, Oncogene.
[214] D. Roden. Pharmacogenetics and drug-induced arrhythmias. , 2001, Cardiovascular research.
[215] Neal J Meropol,et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[216] K. Shen,et al. Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer , 2008 .
[217] L. Seymour,et al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[218] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.
[219] G. Bonadonna,et al. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[220] J. Koeller,et al. Electrocardiographic and Cardiovascular Effects of the 5-Hydroxytryptamine3 Receptor Antagonists , 2003, The Annals of pharmacotherapy.
[221] X. Thomas,et al. Gemtuzumab Ozogamicin (Mylotarg®) as Single Agent Treatment for Adult Patients with Acute Myeloid Leukemia (AML). , 2005 .
[222] T. Ley,et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. , 2001, Blood.
[223] A. Davies,et al. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. , 2008, The oncologist.
[224] A. Gemma,et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[225] A. Kudelka,et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. , 2008, The Lancet. Oncology.
[226] P. Quaglino,et al. Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients. , 2007, Haematologica.
[227] B. Schnetzler,et al. Coronary spasm induced by capecitabine. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[228] G. Wood,et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. , 2001, Archives of dermatology.
[229] Linda Mol,et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. , 2009, The New England journal of medicine.
[230] B. Barlogie,et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. , 2001, Blood.
[231] H. Wieand,et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[232] M. Halushka,et al. Heart failure associated with sunitinib malate , 2008, Cancer.
[233] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[234] S. Srinivas,et al. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate , 2008 .
[235] M. Štěrba,et al. Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron , 2009, Pharmacological reports : PR.
[236] Janice M. Lu,et al. Novel therapies in breast cancer: what is new from ASCO 2008 , 2008, Journal of hematology & oncology.
[237] F. Romano,et al. Interleukin-2 immunotherapy action on innate immunity cells in peripheral blood and tumoral tissue of pancreatic adenocarcinoma patients , 2008, Langenbeck's Archives of Surgery.
[238] D. Keefe. The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern? , 2002, The oncologist.
[239] J. Bergh,et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[240] C. Papadopoulos,et al. Capecitabine-associated coronary vasospasm: a case report , 2008, Emergency Medicine Journal.
[241] P. Bhargava. VEGF kinase inhibitors: how do they cause hypertension? , 2009, American journal of physiology. Regulatory, integrative and comparative physiology.
[242] G. Lip,et al. Assessment of endothelial damage and dysfunction: observations in relation to heart failure. , 2003, QJM : monthly journal of the Association of Physicians.
[243] B. Vincenzi,et al. Gemcitabine-induced atrial fibrillation: a hitherto unreported manifestation of drug toxicity. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[244] D. Dodwell,et al. Etoposide-related myocardial infarction. , 1995, Clinical oncology (Royal College of Radiologists (Great Britain)).
[245] P. Salem,et al. Supraventricular tachycardia. A probable complication of platinum treatment. , 1984, Oncology.
[246] D. Qian,et al. Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias , 2004, Clinical Cancer Research.
[247] D. Richel,et al. Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[248] B. Barlogie,et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. , 2002, Blood.
[249] K. Gelmon,et al. The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines , 2008, Breast Cancer Research and Treatment.
[250] P Kelly Marcom,et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[251] D. Ferrari,et al. Gemcitabine and atrial fibrillation: a rare manifestation of chemotherapy toxicity. , 2006, Anti-cancer drugs.
[252] M. Kris,et al. Gemcitabine-Induced Peripheral Edema: Report on 15 Cases and Review of the Literature , 2003, American journal of clinical oncology.
[253] J. Robert,et al. Results of a phase I study of DTS-201, a peptidic prodrug of doxorubicin, in patients with solid tumors , 2007 .
[254] S. Steinberg,et al. Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell Lymphoma , 2006, Clinical Cancer Research.
[255] R. Pazdur,et al. FDA drug approval summary: erlotinib (Tarceva) tablets. , 2005, The oncologist.
[256] R. Pazdur,et al. Ixabepilone in Combination with Capecitabine and as Monotherapy for Treatment of Advanced Breast Cancer Refractory to Previous Chemotherapies Report from the Fda , 2022 .
[257] M. Duvic,et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[258] Johan Vansteenkiste,et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[259] Nosheen Fatima. CARDIOTOXICITY OF ANTICANCER DRUGS , 2009 .
[260] F. Kabbinavar,et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. , 2007, Journal of the National Cancer Institute.
[261] J. Steinberger,et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. , 2005, Blood.
[262] D. Keefe,et al. Clinical Cardiotoxicity of 5‐Fluorouracil , 1993, Journal of clinical pharmacology.
[263] J. O’Shaughnessy,et al. Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results. , 2002, Clinical breast cancer.
[264] M. Poulsen,et al. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[265] Jean-Pierre Valentin,et al. Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative. , 2009, American heart journal.
[266] M. Ro̸rth,et al. Vascular toxicity and the mechanism underlying Raynaud's phenomenon in patients treated with cisplatin, vinblastine and bleomycin. , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.
[267] E. Shpall,et al. Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[268] I. Çelik,et al. Recurrent Asymptomatic Bradycardia Episodes after Cisplatin Infusion , 2001, The Annals of pharmacotherapy.
[269] S. Cha,et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[270] M. Mego,et al. Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[271] M. Trudeau,et al. Gemcitabine in the management of metastatic breast cancer: a systematic review , 2008, Breast Cancer Research and Treatment.
[272] P. Kouides,et al. Cytarabine-induced pericarditis: a case report and review of the literature of the cardio-pulmonary complications of cytarabine therapy. , 1995, Leukemia research.
[273] A. Gratwohl,et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. , 2007, Blood.
[274] Hannes Kaufmann,et al. Thromboembolic events during treatment with thalidomide. , 2002, Blood.
[275] M. Boccadoro,et al. Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[276] K. Friedrichs,et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[277] F. Dentali,et al. Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura , 2007, Annals of Internal Medicine.
[278] M. Dimopoulos,et al. Adverse effects of thalidomide administration in patients with neoplastic diseases. , 2004, The American journal of medicine.
[279] K. Zervas,et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[280] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.
[281] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[282] B. Leber,et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[283] T. Shepard. Catalog of Teratogenic Agents , 1973 .
[284] D. Thiele,et al. Sudden death during doxorubicin administration , 1979, Cancer.
[285] Chiara Benedetto,et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[286] P. Conte,et al. Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer. , 2009, International journal of radiation oncology, biology, physics.
[287] Bruce D Cheson,et al. Bendamustine: rebirth of an old drug. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[288] M Baum,et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.
[289] Bruce D Cheson,et al. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. , 2008, The New England journal of medicine.
[290] L. Vaickus,et al. Pericarditis induced by high-dose cytarabine therapy. , 1984, Archives of internal medicine.
[291] D. Sebag‐Montefiore,et al. Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[292] J. Crowley,et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[293] G. Bonadonna,et al. Phase II evaluation of adriamycin in human neoplasia , 1973, Cancer.
[294] A. Wåhlin,et al. Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia , 2004, Cancer Chemotherapy and Pharmacology.
[295] Claude Denham,et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[296] R. Nesto,et al. Recombinant alpha 2 interferon-related cardiomyopathy. , 1988, The American journal of medicine.
[297] M. Elisaf,et al. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. , 2001, European journal of cancer.
[298] J. Whitworth,et al. Pressor responsiveness in corticosteroid-induced hypertension in humans. , 1992, Hypertension.
[299] J. Baselga,et al. Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy , 2005, Clinical Cancer Research.
[300] K. Höffken,et al. Severe non-haematological toxicity after treatment with gemcitabine , 1999, Journal of Cancer Research and Clinical Oncology.
[301] Lyndsay Harris,et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[302] M. Djaldetti,et al. Vincristine‐induced myocardial infarction , 1975, Cancer.
[303] M. Campone,et al. Vinflunine: A New Microtubule Inhibitor Agent , 2008, Clinical Cancer Research.
[304] H. Sørensen,et al. Tamoxifen Treatment in Danish Breast Cancer Patients and 5-Year Risk of Arterial Atherosclerotic Events: A Null Association , 2008, Cancer Epidemiology Biomarkers & Prevention.
[305] Jm Dippenaar,et al. Local anaesthetic toxicity , 2007 .
[306] M. Grever,et al. Cardiotoxicity of Histone Deacetylase Inhibitor Depsipeptide in Patients with Metastatic Neuroendocrine Tumors , 2006, Clinical Cancer Research.
[307] I. Bernstein,et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence , 2005, Cancer.
[308] E. Perez,et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. , 2008, Mayo Clinic proceedings.